Drug Profile
Research programme: protein kinase inhibitors - Deciphera Pharmaceuticals
Alternative Names: DCC 2721; DCC-2157; DP-3407; DP-3429; DP-3556; DP-3590; DP-4178; DP-4610; DP-4904Latest Information Update: 09 Jan 2023
Price :
$50
*
At a glance
- Originator Deciphera Pharmaceuticals
- Class Small molecules
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Colony stimulating factor inhibitors; Macrophage colony stimulating factor receptor antagonists; Mitogen activated protein kinase 14 inhibitors; Mitogen activated protein kinase 3 inhibitors; P38 mitogen-activated protein kinase inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c-akt inhibitors; Proto oncogene protein c-kit inhibitors; Proto-oncogene protein c-met inhibitors; TIE 2 receptor antagonists; Vascular endothelial growth factor receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Gastrointestinal stromal tumours
Highest Development Phases
- Preclinical Cancer
- No development reported Cancer metastases; Gastrointestinal stromal tumours; Solid tumours
- Discontinued Autoimmune disorders; Inflammation; Rheumatoid arthritis
Most Recent Events
- 03 Jan 2023 Protein kinase inhibitors are still in preclinical phase for cancer in USA
- 03 Jan 2023 Deciphera pharmaceuticals announces intention to nominate a new development candidate from its discovery engine of novel switch-control inhibitors in the first half of 2023
- 28 Jun 2021 No recent reports of development identified for preclinical development in Cancer in USA